A vaccine is a biological preparation of killed forms of microbes, living attenuated organisms, living fully virulent organisms, a microbe’s toxins or one of its surface proteins. Vaccines play a key role in improving immunity against particular diseases. Therefore, vaccination is promoted as a vital public health intervention throughout the globe. According to the World Health Organization (WHO), vaccination has reduced the burden of infectious disease globally to a great extent. According to a study conducted by Zhou et al, vaccination prevented 42,000 early deaths and approximately 20 million cases of diseases in children born in the U.S. in 2009, resulting in saving USD 13.5 billion in direct medical and non-medical costs and USD 68.8 billion in total societal costs.
This report on the U.S. vaccine market offers an insightful and in-depth assessment of the current as well as future market potential of human as well as animal vaccine markets. The human vaccine market is further segmented into pediatric and adult vaccine markets, based on vaccine type. On the basis of different antigens, the U.S. human vaccine market has been categorized into hepatitis, influenza, meningococcal, pneumococcal, human papillomavirus (HPV), combination vaccines and others. The U.S. animal vaccine market is broadly segmented as companion animal and livestock vaccine markets. The U.S. companion animal vaccine market segment has been further categorized into canine and feline, while the livestock vaccine market has been divided into porcine, bovine, ovine, poultry and equine markets.
Each of these segments and sub-segments has been extensively analyzed in the report, considering factors such as market trends, recent developments, future outlook and opportunities. The report provides market revenue size in terms of USD million for each segment and sub-segment for the period 2012 to 2020. In addition, the compounded annual growth rate (CAGR) of the overall U.S. vaccine market and various segments and sub-segments has also been provided in the report for the forecast period 2014 to 2020, considering 2012 and 2013 as the base years. Extensive pricing analysis for human as well as animal vaccine market has been provided in the report.
This report includes an elaborate executive summary, which covers a market snapshot representing key findings from the study on the U.S. vaccine market. The market overview section of the report on the U.S. vaccine market comprises qualitative analysis of the overall market considering factors determining market dynamics such as growth drivers, restraints and opportunities. The market overview chapter also includes a section describing the vaccine approval and regulatory pathway in the U.S. The competitive landscape section has been provided for both human and animal vaccine markets. This section presents the market revenue share of key players in terms of percentage for the year 2013. The market share analysis of key players involved the study of company product portfolio and sales revenue along with market developments such as new product launch and regulatory approvals.
This study on the U.S. vaccine market suggests a list of recommendations for new companies willing to enter the market and for existing companies to accentuate revenue shares, which is likely to help in the decision-making process. The report concludes with the profiles of major players in the U.S. vaccine market such as GlaxoSmithKline plc, Merck & Co., Inc., Novartis International AG, Pfizer, Ltd., Sanofi, Boehringer Ingelheim and Zoetis, Inc. Each company profile in the report contains information such as company overview, financial overview, product portfolio, business strategies and recent developments. The company overview section comprises basic information about the company such as major business areas, company’s brief history and its establishment year, number of employees and geographical presence. In the financial overview section, information such as selling and general administrative expenses, R&D expenses and annual revenue for the last three consecutive years (2011, 2012 and 2013) has been provided. The business strategies section mentions key strategies adopted by the company in the past to strengthen its position in the vaccine market. The recent development section gives information about the recent happening in the company related with the vaccine market.
The U.S. vaccine market is segmented as follows: